Oculis Highlights Unmet Needs in DME Treatment with Delphi Study Findings

Event summary

  • Oculis presented findings from the DME AWARE Delphi study at ARVO 2026, highlighting unmet needs in diabetic macular edema (DME) management.
  • The study, involving 25 retina and ophthalmology experts, identified non-invasive treatment options and early intervention as critical priorities.
  • Oculis is on track to report topline results from the DIAMOND Phase 3 trials for OCS-01, a potential first-in-class eye drop therapy for DME, in June 2026.
  • DME AWARE findings underscore the need for non-invasive therapies to address the 60% of patients untreated one year post-diagnosis and the 40% with inadequate treatment response to anti-VEGF therapies.

The big picture

Oculis' findings from the DME AWARE Delphi study underscore the significant unmet needs in DME management, particularly the lack of non-invasive treatment options for early intervention. With the upcoming topline results from the DIAMOND Phase 3 trials, Oculis aims to transform the current treatment paradigm for DME, addressing the challenges of inadequate treatment response and the invasive nature of current therapies. The study's global expert consensus highlights the growing interest in less invasive options to improve patient care and treatment outcomes in this progressive and irreversible condition.

What we're watching

Clinical Trial Outcomes
Whether the June 2026 topline results from the DIAMOND Phase 3 trials will validate OCS-01 as a non-invasive treatment option for DME.
Market Adoption
The pace at which non-invasive therapies like OCS-01 could be adopted if proven effective, addressing the current gaps in DME management.
Regulatory Pathway
How Oculis navigates the regulatory approval process for OCS-01, given its novel approach as an eye drop therapy for DME.